Kick­back, bribery and rack­e­teer­ing charges are fol­lowed by a CRL for opi­oid spray at scan­dal-plagued In­sys

Over the past 9 months In­sys Ther­a­peu­tics $IN­SY founder John Kapoor was charged with rack­e­teer­ing and bribery, com­pa­ny staffers plead­ed guilty on a kick­back scheme and the feds al­lied with com­pa­ny whistle­blow­ers claim­ing that free din­ners and en­ter­tain­ment were lav­ished on some doc­tors to en­cour­age them to pre­scribe more of their fen­tanyl nasal spray.

And on Fri­day af­ter­noon the FDA joined in the act, re­ject­ing the com­pa­ny’s ap­pli­ca­tion for buprenor­phine sub­lin­gual spray as a pain rem­e­dy, which the com­pa­ny says was due to un­spec­i­fied safe­ty con­cerns. The CRL high­light­ed the sta­tis­ti­cal­ly sig­nif­i­cant ef­fi­ca­cy da­ta, In­sys claimed in its state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.